Product Code: PHA0576
The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 149-page report you will receive 143 charts- all unavailable elsewhere.
The 149-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
- Global Acute Myeloid Leukaemia Market forecast to 2029
- Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
- Chemotherapy: Cytarabine, Daunorubicin, Others
- Targeted Therapy: Midostaurin, Enasidenib, Others
- This report provides individual revenue forecasts to 2029 for these regional and national markets:
- North America: US, Canada, and Mexico
- Europe: Germany, France, United Kingdom, Italy, Spain and rest of Europe
- Asia-Pacific: Japan, China, India, Australia and Rest of Asia-Pacific
- LAMEA: GCC, Brazil, South Africa, Rest of LAMEA
Each national market forecast is further segmented by type: chemotherapy and targeted therapy.
- Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
- Bristol-Myers Squibb Company
- Clavis Pharma ASA
- Daiichi Sankyo
- Sunesis Pharmaceuticals
- This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.
- This report discusses Porter's Five Forces analysis of the acute myeloid leukaemia market.
- This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.
- Key questions answered in this report:
- How is the Acute myeloid leukemia market evolving?
- What are the drivers and restraints for the growth of the acute myeloid leukemia market?
- What are the market shares of each segment of the overall acute myeloid leukemia market in 2019?
- How will each acute myeloid leukemia submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
- How will the market shares for each acute myeloid leukemia submarket develop from 2019 to 2029?
- What is the value of the leading acute myeloid leukemia segments in important regions of the world?
- What will be the main driver for the overall market from 2019 to 2029?
- How will political and regulatory factors influence the regional markets and submarkets?
- How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029?
- Who are the leading players and what are their prospects over the forecast period?
- How will the industry evolve during the period between 2019 and 2029?
Visiongain's study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.
Table of Contents
1. Report Overview
- 1.1 Global Leukemia Market Overview
- 1.2 Market Definition and Scope
- 1.3 Why you should read this report?
- 1.4 How the report delivers?
- 1.5 Key Questions Answered in this Report
- 1.6 Who is the report for?
- 1.7 Report and Analysis Method
- 1.8 Frequently Asked Questions
- 1.9 Some Associated Reports
- 1.10 About Visiongain
2. Acute Myeloid Leukemia Market Overview
- 2.1 Introduction
- 2.1.1 French-American-British (FAB) classification
- 2.1.2 WHO Classification of AML
- 2.2 Epidemiology of AML
- 2.3 Treatment for AML
- 2.3.1 Medication Overview
3. Global Acute Myeloid Leukemia Market Forecast to 2029 - Based on Drug Type
- 3.1 Chemotherapy Based AML Therapeutics Market, 2019-2029
- 3.1.1 Cytarabine
- 3.1.2 Daunorubicin
- 3.1.3 Other Chemotherapy Drugs
- 3.2 Targeted therapy Market for AML Therapeutics - 2019-2029
- 3.2.1 Midostaurin
- 3.2.2 Enasidenib
- 3.2.3 Other targeted therapy
- 3.3 Other drugs used in the treatment of AML
4. Global AML Therapeutics Market Forecast to 2029 - Regional and National Market
- 4.1 North America AML Therapeutics Market Forecast, 2019-2029
- 4.1.1 USA AML Therapeutic Market Forecast, 2019-2029
- 4.1.2 Canada AML Therapeutic Market Forecast, 2019-2029
- 4.1.3 Mexico AML Therapeutic Market Forecast, 2019-2029
- 4.2 Europe AML Therapeutics Market Forecast, 2019-2029
- 4.2.1 Germany AML Therapeutics Market Forecast, 2019-2029
- 4.2.2 UK AML Therapeutics Market Forecast, 2019-2029
- 4.2.3 Italy AML therapeutics Market Forecast, 2019-2029
- 4.2.4 France AML Therapeutics Market Forecast, 2019-2029
- 4.2.5 Spain AML Therapeutics Market, 2019-2029
- 4.2.6 Rest of Europe AML Therapeutics Market Forecast, 2019-2029
- 4.3 Asia Pacific AML Therapeutics Market Forecast, 2019-2029
- 4.3.1 Japan AML Therapeutics Market Forecast, 2019-2029
- 4.3.2 China AML Therapeutics Market Forecast, 2019-2029
- 4.3.3 India AML Therapeutics Market Forecast, 2019-2029
- 4.3.4 Australia AML Therapeutics Market Forecast, 2019-2029
- 4.3.5 Rest of Asia Pacific AML Therapeutic Market Forecast, 2019-2029
- 4.4 Latin America and Middle East Africa AML Therapeutics Market Forecast, 2019-2029
- 4.4.1 GCC AML Therapeutics Market Forecast, 2019-2029
- 4.4.2 Brazil AML Therapeutics Market Forecast, 2019-2029
- 4.4.3 South Africa AML Therapeutics Market Forecast, 2019-2029
- 4.4.4 Rest of LAMEA AML Therapeutics Market, 2019-2029
5. Company Profiles
- 5.1 Daiichi Sankyo
- 5.1.1 Company Overview
- 5.1.2 Financial Overview
- 5.1.3 Recent Strategic Developments
- 5.2 Celgene Corporation
- 5.2.1 Company Overview
- 5.2.2 Operational Segments
- 5.2.3 Financial Overview
- 5.2.4 Recent Developments
- 5.3 Teva Pharmaceuticals
- 5.3.1 Company Profile
- 5.3.2 Operational Segments
- 5.3.3 Financial Highlights
- 5.3.4 Recent Developments
- 5.4 Eisai., Co. Ltd.
- 5.4.1 Company Overview
- 5.4.2 Operational Segments
- 5.4.3 Financial Overview
- 5.5 Novartis AG
- 5.5.1 Company Profile
- 5.5.2 Operational Segments
- 5.5.3 Financial Highlights
- 5.5.4 Recent Developments
- 5.6 GlaxoSmithKline Inc
- 5.6.1 Company Overview
- 5.6.2 Operating Segments
- 5.6.3 Financial Highlights
- 5.7 Sunesis Pharmaceuticals
- 5.7.1 Company Profile
- 5.7.2 Operational Segments
- 5.7.3 Financial Overview
- 5.8 Clavis Pharma ASA
- 5.9 F. Hoffman-La Roche Ltd.
- 5.9.1 Company Profile
- 5.9.2 Operational Segments
- 5.9.3 Financial Analysis
- 5.9.4 Recent Strategic Development
- 5.10 Bristol-Myers Squibb
- 5.10.1 Company Profile
- 5.10.2 Financial Overview
6. Acute Myeloid Leukemia: Qualitative Analysis
- 6.1. Market Drivers
- 6.1.1 The rise in Cases of Chronic Diseases
- 6.1.2 Research for Innovative Therapeutics
- 6.1.3 Increase in the geriatric population
- 6.2 Market Restraints
- 6.2.1 The adverse effect of the treatment
- 6.3 Market Opportunities
- 6.3.1 Unmet Oncological Demand
- 6.3.2 Untapped Opportunities in developing countries
7. Industry Analysis of the Market Players (Porter's Five Force Analysis)
- 7.1 Bargaining Power of Suppliers
- 7.2 The threat of New Entrants
- 7.3 The threat of Substitute for Product
- 7.4 Bargaining Power of Buyers
- 7.5 Bargaining Power of Suppliers
8. Pipeline and Clinical trial Analysis
- 8.1 Pipeline Analysis
- 8.1.1 Vosaroxin (Sunesis Pharmaceuticals)
- 8.1.2 CPX-351 (Celator Pharmaceuticals)
- 8.1.3 Sepacitabine (Cyclacel)
- 8.1.4 SGI-110 (Astex)
- 8.2 Small Molecule Targeted Therapy
- 8.2.1 Volasertib (Boehringer Ingelheim)
- 8.3 Isocitrate Dehydrogenase Inhibitor
- 8.3.1 ABT -199s (AbbVie, Roche)
- 8.3.2 FLT3 Inhibitors
- 8.3.3 Sorafenib (Bayer, Onyx Pharmaceuticals)
- 8.3.4 Midostaurin (Novartis)
- 8.3.5 Quizartinib (Daiichi Sankyo)
- 8.4 Monoclonal Antibodies
- 8.4.1 SGN-33A (Seattle Genetics)
- 8.4.2 AMG-330 (Amgen)
- 8.5 Clinical Trials
- Associated Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain Report Evaluation Form